openPR Logo
Press release

Scleroderma Market Reach USD 3,468.3 million by 2031, Growing with 6.2% CAGR - Pfizer, Inc., Sanofi, GlaxoSmithKline plc.

12-20-2024 08:24 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Scleroderma Market

Scleroderma Market

The Scleroderma Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Scleroderma market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/scleroderma-market

The Global Scleroderma Market size reached USD 2,169.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,468.3 million by 2031. The Scleroderma market is expected to exhibit a CAGR of 6.2% during the forecast period (2024-2031).

Scleroderma is a rare autoimmune disease characterized by the hardening and tightening of skin and connective tissues. It can also affect internal organs, including the lungs, heart, and digestive tract. The exact cause is unknown, but it involves an overproduction of collagen. Symptoms range from skin thickening and joint pain to organ dysfunction. While there is no cure, treatments focus on managing symptoms and improving quality of life through medication and therapy.

Competitive Landscape

The section also contains information related to the new product launches, mergers, acquisitions, collaborations, etc., to give a clear understanding about the competitive landscape prevailing in the global market. With an emphasis on strategies there have been several primary developments done by major companies such as

Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Cumberland Pharmaceuticals, Inc., Actelion Pharmaceuticals, Inc.(Johnson & Johnson), Boehringer Ingelheim International GmbH(C.H. Boehringer Sohn Ag & Co. KG), Corbus Pharmaceuticals Holdings, Inc., Bayer AG, Gilead Sciences, Inc. and Allergan, Inc. (Abbvie)

Key Developments:

❁ In September 2022, Sanofi, a French multinational pharmaceutical and healthcare company, and Kadmon, a biopharmaceutical corporation, announced their decision to merge. Following the acquisition, Sanofi was expected to continue the development of belumosudil (KD025), a treatment for diffuse cutaneous systemic sclerosis (dcSSc). This merger aims to strengthen Sanofi's portfolio and accelerate the progress of therapies for autoimmune diseases.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/scleroderma-market

Market Segments

The detailed segmentation offered in the report will help customers get a clear idea about the market segments and the factors that will drive segmental growth. The Scleroderma market has been segmented

By Disease Type: Localized Scleroderma, Systemic Scleroderma

By Treatment: Medication, Surgery & Other Therapies

By End User: Hospital, Retail and Online Pharmacies, Others

Research Process

Both primary and secondary data sources have been used in the global Scleroderma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Regional Analysis for Scleroderma Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Scleroderma market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Scleroderma Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Scleroderma market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Scleroderma Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock Year-End Savings! Get Up to 30% Off: https://www.datamintelligence.com/buy-now-page?report=scleroderma-market

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Scleroderma market?

➠ Who are the global key manufacturers of the Scleroderma Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Scleroderma market opportunities and threats faced by the vendors in the global Scleroderma Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Scleroderma market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Scleroderma Market Reach USD 3,468.3 million by 2031, Growing with 6.2% CAGR - Pfizer, Inc., Sanofi, GlaxoSmithKline plc. here

News-ID: 3793539 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Plant Breeding and CRISPR Plant Market Outlook 2024-2031: Innovations in Genome Editing, Crop Yield, and Sustainable Agriculture | Bayer AG, BASF, Syngenta Crop Protection AG.
United States Plant Breeding and CRISPR Plant Market Outlook 2024-2031: Innovati …
Plant Breeding and CRISPR Plant Market is forecasted to reach at a CAGR of 10.87% during the forecast period (2024-2031). This market focuses on improving crop yield, quality, and resistance through modern breeding techniques and CRISPR-based genome editing. Plant breeding innovations support food security by developing climate-resilient and pest-resistant varieties. CRISPR technology enables precise genetic modifications, reducing time compared to conventional breeding. Market growth is driven by increasing global food demand
Recent Developments in Neuromorphic Computing: Intel, IBM, Qualcomm, Fujitsu, Sony, and Global Research Institutions Driving Innovation
Recent Developments in Neuromorphic Computing: Intel, IBM, Qualcomm, Fujitsu, So …
The Global Neuromorphic Computing Market reached USD 48.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 6,801.9 million by 2030. The global neuromorphic computing market is expected to exhibit a CAGR of 91.5% during the forecast period (2024-2031). The neuromorphic computing market revolves around hardware and systems modeled on the human brain's neural architecture, enabling advanced processing and learning capabilities. These systems aim to
Strategic Collaborations in Electric Aircraft Charging Infrastructure: Partnerships Between Aerospace Firms, Energy Companies, and Airports | Rolls-Royce Holdings Plc, Beta Technologies, Electro.Aero Pty Ltd.
Strategic Collaborations in Electric Aircraft Charging Infrastructure: Partnersh …
Global Electric Aircraft Charging Interfaces Market reached USD 0.54 billion in 2023 and is expected to reach USD 2.1 billion by 2031 growing with a CAGR of 20.7% during the forecast period 2024-2031. This market involves charging systems and interfaces that enable electric and hybrid-electric aircraft to recharge efficiently and safely. With the aviation industry pushing toward sustainable solutions, these interfaces are critical for commercial, private, and urban air mobility vehicles.
Anti-Obesity Drugs Market Recent Developments 2025: Key Updates from the U.S., Europe, Japan, and Asia-Pacific | Major Companies are Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb
Anti-Obesity Drugs Market Recent Developments 2025: Key Updates from the U.S., E …
Global Anti-Obesity Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030 growing with a CAGR of 45.5% during the forecast period 2024-2031. The anti-obesity drugs market includes pharmaceuticals designed to promote weight loss by suppressing appetite, reducing fat absorption, or enhancing energy expenditure. Rising global obesity rates, linked to sedentary lifestyles and unhealthy diets, are driving market demand. Approved drugs include orlistat,

All 5 Releases


More Releases for Scleroderma

Key Factor Supporting Scleroderma Market Development in 2025: Rising Scleroderma …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Scleroderma Market Size By 2025? The market size of scleroderma has notably expanded in past years. It is projected to rise from a value of $2.33 billion in 2024 up to $2.49 billion in 2025, posting a compound annual growth rate (CAGR) of 6.9%. The
Scleroderma Market Trends, Size, Share And Analysis 2024-2033
"The new report published by The Business Research Company, titled Scleroderma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to
Scleroderma Therapeutics Market, By Indication (Localized Scleroderma, Systemic …
Scleroderma therapeutics market size is projected to grow at a compound annual growth rate of 5.7% over the forecast period of 2021 to 2028. Data Bridge Market Research report on scleroderma therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market's growth. View Detailed Report: https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market Scleroderma is a rare auto-immune disease which is generally characterized by
Scleroderma Therapeutics Market, By Indication (Localized Scleroderma, Systemic …
Scleroderma therapeutics market size is projected to grow at a compound annual growth rate of 5.7% over the forecast period of 2021 to 2028. Data Bridge Market Research report on scleroderma therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market's growth. View Detailed Report: https://www.databridgemarketresearch.com/reports/global-scleroderma-therapeutics-market Scleroderma is a rare auto-immune disease which is generally characterized by
Scleroderma Pipeline | 20+ Key Players & 22+ Pipeline Drugs | DelveInsight
DelveInsight's, "Scleroderma Pipeline Insight, 2022," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key takeaways from the Scleroderma Pipeline Insight Report • DelveInsight's analysis depicts a robust
Scleroderma Therapeutics Market Analysis - Forecast to 2026
As per the research conducted by GME, the Global Scleroderma Therapeutics Market will grow with a CAGR value of 6.1 percent. Moreover, the rising R&D activities along with the advancing technology and increasing government spending in the pharma industry has boosted the market and growth will be seen in the future. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Scleroderma Therapeutics Market